Internal Mutations and Microbes May Drive a Distinct Subtype of Oral Cancer

Why It Matters

Recognizing NIRF oral cancer as a separate molecular entity highlights unmet diagnostic needs and opens pathways for targeted treatments, potentially improving outcomes for patients who lack classic risk exposures.

Key Takeaways

• NIRF oral cancers lack smoking, HPV risk factors
• Aging‑related SBS1 and APOBEC SBS2/13 signatures dominate NIRF tumors
• Microbial signatures and antimicrobial pathways suggest oral microbiome involvement
• Immune‑evasion traits may limit checkpoint‑inhibitor efficacy
• APOBEC‑driven mutagenesis points to DNA‑damage‑response therapeutic targets

Pulse Analysis

The epidemiology of oral cavity squamous cell carcinoma is shifting. While tobacco, alcohol and high‑risk HPV have long explained the majority of cases, a growing cohort—particularly younger women—presents without any of these exposures. This demographic change prompted investigators to interrogate large public datasets, revealing that roughly a quarter of oral tumors fall into a "no identified risk factor" (NIRF) category. By applying mutational signature analysis, the team uncovered that internal processes, not external carcinogens, are the primary drivers of these cancers.

At the molecular level, NIRF tumors are characterized by two dominant signatures. The ubiquitous SBS1 pattern reflects spontaneous deamination linked to cellular aging, while SBS2 and SBS13 trace APOBEC enzyme activity, a known source of cytidine‑to‑uracil editing that fuels genomic instability. Intriguingly, histopathology also detected bacterial fragments within the tumor microenvironment, and gene‑expression profiling highlighted up‑regulated antimicrobial and keratinization pathways. Together, these findings suggest that the oral microbiome—or its dysbiosis—may act as a co‑factor, providing a novel angle for research into carcinogenesis beyond traditional mutagens.

Clinically, the NIRF subtype poses both challenges and opportunities. Immune‑evasion alterations, such as disrupted antigen‑presentation machinery, could blunt responses to current checkpoint‑inhibitor regimens, urging the development of combination strategies. Conversely, the prevalence of APOBEC‑mediated mutagenesis points to susceptibility to agents that exploit DNA‑damage‑response weaknesses, such as ATR or PARP inhibitors. As precision oncology matures, integrating mutational signature profiling into routine pathology could enable oncologists to stratify patients more accurately, tailoring therapy to the underlying biology rather than historical risk factors. Future trials will need to validate these therapeutic hypotheses and explore microbiome‑modulating interventions as adjuncts to standard care.